Dexcom (DXCM) Cash from Investing Activities Growth (1y) (2011 - 2026)
Dexcom (DXCM) Cash from Investing Activities Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 200.50 Bn | 194.89 Bn | 7.27 Bn | -15.64% |
| 2 | Stryker | 130.00 Bn | 126.52 Bn | 4.50 Bn | -514.42% |
| 3 | Medtronic | 120.36 Bn | 111.14 Bn | 6.41 Bn | -87.14% |
| 4 | Boston Scientific | 74.19 Bn | 73.65 Bn | 3.85 Bn | -73.71% |
| 5 | Edwards Lifesciences | 52.73 Bn | 48.48 Bn | 1.35 Bn | -12.26% |
| 6 | Dexcom | 34.64 Bn | 32.70 Bn | 830.00 Mn | 618.55% |
| 7 | GE HealthCare Technologies | 34.13 Bn | 32.02 Bn | 2.18 Bn | 48.43% |
| 8 | Koninklijke Philips | 26.52 Bn | 23.20 Bn | 4.55 Bn | 91.33% |
| 9 | Steris | 23.23 Bn | 22.75 Bn | 684.20 Mn | 0.00% |
| 10 | Zimmer Biomet Holdings | 19.39 Bn | 18.98 Bn | 1.54 Bn | 86.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 618.55% |
| Mar 31, 2026 | -397.90% |
| Dec 31, 2025 | 200.95% |
| Sep 30, 2025 | -8.32% |
| Jun 30, 2025 | 66.33% |
| Mar 31, 2025 | 33.96% |
| Dec 31, 2024 | -173.20% |
| Sep 30, 2024 | 217.16% |
| Jun 30, 2024 | 66.02% |
| Mar 31, 2024 | 140.06% |
| Dec 31, 2023 | 313.76% |
| Sep 30, 2023 | -178.28% |
| Jun 30, 2023 | -283.64% |
| Mar 31, 2023 | 54.66% |
| Dec 31, 2022 | 60.87% |
| Sep 30, 2022 | 690.69% |
| Jun 30, 2022 | -139.90% |
| Mar 31, 2022 | -267.02% |
| Dec 31, 2021 | -1,967.08% |
| Sep 30, 2021 | 411.83% |